<DOC>
	<DOCNO>NCT02874651</DOCNO>
	<brief_summary>This study enroll patient non-metastatic nasopharyngeal carcinoma ( NPC ) residual Epstein-Barr virus ( EBV ) DNA curative radiotherapy chemoradiotherapy . The purpose evaluate survival patient treat apatinib ( YN968D1 ) , inhibitor vascular endothelial growth factor receptor ( phase IIa ) compare survival patient treat apatinib versus placebo ( phase IIb ) .</brief_summary>
	<brief_title>ADjuVant Apatinib Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus ( EBV ) DNA Following Radiotherapy</brief_title>
	<detailed_description>This study two part . In single arm phase IIa part , enroll 25 patient residual Epstein-Barr virus ( EBV ) DNA curative radiotherapy chemoradiotherapy . All patient receive apatinib . The purpose evaluate disease free-survival ( DFS ) patient treat apatinib . In phase IIb part , patient randomize apatinib placebo ratio 1:1 . The estimated sample size 78 phase IIb . However , final sample size phase IIb determine base result phase IIa part .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<criteria>1 . Biopsy proven nasopharyngeal carcinoma , detectable pretreatment plasma EBV DNA 2 . Have detectable plasma EBV DNA end ( +/ 1 week ) curative radiotherapy chemoradiotherapy ( radiation dose &gt; 66Gy ) , determined central lab 3 . No clinical evidence persistent locoregional disease 4 . No evidence distant metastasis , base upon skeletal scintigraphy , chest Xray examination , liver ultrasound appropriate workup ( e.g. , CT , MRI positron emission tomography ( PET ) /CT ] ) within 21 day prior registration 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 6 . Anticipated survival &gt; = 3 month 7 . Absolute neutrophil count ( ANC ) &gt; = 1,500 cells/mm^3 8 . Platelets &gt; 80,000 cells/mm^3 9 . Hemoglobin &gt; = 8.0 g/dl ( transfusion within last 14 day ) 10 . Total bilirubin = &lt; 1.5 x institutional upper limit normal ( ULN ) 11 . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) = &lt; 2.5 x institutional ULN 12 . Creatinine clearance ( CC ) &gt; = 50 ml/min estimate CockcroftGault formula 1 . Patients stage IIIIV disease ( American Joint Committee On Cancer/Union International Cancer Control 7th ) contraindication chemotherapy n't receive platinum base concurrent chemotherapy radiation 2 . Patients tumor possibly invade main vessel ( e.g . encasement internal jugular artery/vein ) diagnosis ; tumor , judgment investigator , likely invade main vessel cause lifethreatening hemorrhage event study 3 . History serious hemorrhage event grade 3 high hemorrhage within 4 week prior registration 4 . Hypertension could n't well control single medication ; unstable angina ; angina diagnose within last 3 month ; myocardial infarction within last 6 month ; cardiac arrhythmia need longterm medication ; grade 2 high cardiac dysfunction ( NYHA ) 5 . Proteinuria 6 . Coagulation dysfunction predisposition hemorrhage ; treatment anticoagulation medication vitamin K antagonist ; low dose warfarin ( 1mg po qd ) aspirin ( le 100mg daily ) permit long international normalize ratio ( INR ) = &lt; 1.5 7 . Thrombosis within last 1 year , except cure vein thrombosis relate vein indwell catheter 8 . Unhealed bone fracture chronic unhealed wound 9 . Illness would interfere oral medication , include dysphagia , chronic diarrhea , ileus 10 . Pregnant lactate woman 11 . Women childbearing potential men sexually active willing/able use medically acceptable form contraception within 6 month study 12 . Current drug abuse mentally disable 13 . History congenital acquire immune deficiency disease organ transplantation 14 . Major medical illness , investigator 's opinion would endanger patient interfere completion therapy follow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Nasopharyngeal Carcinoma</keyword>
	<keyword>EB Virus</keyword>
	<keyword>DNA</keyword>
	<keyword>vascular endothecial growth factor receptor inhibitor</keyword>
	<keyword>Apatinib</keyword>
</DOC>